Medicenna Therapeutics Corp (MDNA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Medicenna Therapeutics Corp (MDNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8288
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company. The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132. Medicenna also offers clinical trial services. The company develops cytokines to deliver cell killing payloads to the bulk tumor, tumor microenvironment (TME), and cancer stem cells (CSC). It offers products in therapeutic areas including CNS cancers in glioblastoma multiforme, brain metastasis, padiatric gliloma, blood cancers, solid tumors, and bladder cancers. The company has operations in Canada and the US. Medicenna is headquartered in Toronto, Ontario, Canada.

Medicenna Therapeutics Corp (MDNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Licensing Agreements 11
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11
Equity Offering 12
Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12
Acquisition 13
A2 Acquisition Acquires Medicenna Therapeutics 13
Medicenna Therapeutics Corp – Key Competitors 14
Medicenna Therapeutics Corp – Key Employees 15
Medicenna Therapeutics Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Aug 13, 2018: Medicenna announces first quarter fiscal 2019 financial results 17
Jun 27, 2018: Medicenna Reports March 31, 2018 Year-End Results 19
Feb 12, 2018: Medicenna Reports Third Quarter Fiscal 2018 Financial Results 21
Nov 13, 2017: Medicenna Reports Second Quarter Fiscal 2018 Financial Results 23
Aug 09, 2017: Medicenna Reports First Quarter Fiscal 2018 Financial Results 25
Jun 16, 2017: Medicenna Announces March 31, 2017 Year End Results 26
Corporate Communications 28
Oct 18, 2017: Medicenna Announces Trading on the OTCQX Best Market in the United States 28
Sep 21, 2017: Medicenna Appoints Dr. William Li to Board of Directors 29
Jul 17, 2017: Medicenna Bolsters Management Team 30
May 25, 2017: Medicenna Therapeutics Opens the Market 31
Mar 08, 2017: Medicenna shares resume trading under the symbol “MDNA” 32
Jan 18, 2017: Medicenna Further Strengthens Management Team 33
Jan 17, 2017: Medicenna Announces Additions to the Board of Directors 34
Clinical Trials 35
Jun 08, 2017: Medicennas Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology 35
Apr 20, 2017: Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017 36
Apr 13, 2017: Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Medicenna Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11
Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12
A2 Acquisition Acquires Medicenna Therapeutics 13
Medicenna Therapeutics Corp, Key Competitors 14
Medicenna Therapeutics Corp, Key Employees 15
Medicenna Therapeutics Corp, Subsidiaries 16

List of Figures
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Medicenna Therapeutics Corp (MDNA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United Technologies Corp (UTX):電力:M&Aディール及び事業提携情報
    Summary United Technologies Corp (UTC) is a provider of technology products and services for applications in the aerospace and building systems industries. The company’s building systems portfolio includes elevators and escalators, moving walkways, heating, ventilating, air conditioning (HVAC) and r …
  • Cielo Wind Power, LP:電力:M&Aディール及び事業提携情報
    Summary Cielo Wind Power, LP (Cielo Wind) is a wind power project development company. It designs, develops, owns and operates utility-grade wind power projects. The company provides a wide range of services including engineering, construction, operations and maintenance, land procurement, meteorolo …
  • Norwegian Air Shuttle ASA:企業の戦略・SWOT・財務分析
    Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report Summary Norwegian Air Shuttle ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Smurfit Kappa Group plc:企業の戦略・SWOT・財務情報
    Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report Summary Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • S.A. Industrias Celulosa Aragonesa:企業の戦略・SWOT・財務情報
    S.A. Industrias Celulosa Aragonesa - Strategy, SWOT and Corporate Finance Report Summary S.A. Industrias Celulosa Aragonesa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Siemens AG (SIE):製薬・医療:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Complix NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Complix NV (Complix) is a biopharmaceutical company that discovers and develops alphabodies and pre-clinical programs. The company’s products comprise CMPX-1023, a novel alphabody for autoimmune diseases, and cell penetrating alphabodies for the treatment of cancer, among others. It designs …
  • Polpharma SA:企業の戦略的SWOT分析
    Polpharma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Anteo Diagnostics Ltd (ADO):医療機器:M&Aディール及び事業提携情報
    Summary Anteo Diagnostics Ltd (Anteo Diagnostics) is a leading medical technology company that develops and commercializes healthcare products. The company along with its subsidiaries provides immunoassays, in-vitro diagnostics, and point of care (PoC) tests to life sciences, bio-separation, clinica …
  • Kawasaki Kisen Kaisha, Ltd. (9107)-石油・ガス分野:企業M&A・提携分析
    Summary Kawasaki Kisen Kaisha, Ltd. (K Line) is a global logistics company. K Line’s business lines include land transportation, air transportation, marine transportation, and harbor transportation. It owns and operates dry bulk carriers, LNG carriers, tankers, car carriers and containerships. The c …
  • Konecranes Plc
    Konecranes Plc - Strategy, SWOT and Corporate Finance Report Summary Konecranes Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Performance Food Group:企業の戦略・SWOT・財務分析
    Performance Food Group - Strategy, SWOT and Corporate Finance Report Summary Performance Food Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Peregrine Holdings Ltd:企業の戦略・SWOT・財務分析
    Peregrine Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Peregrine Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Parion Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Parion Sciences Inc (Parion Sciences) is a development stage company that provides research, development and commercialization of treatments to improve patient’s innate mucosal surface defenses. The company’s pipeline products include P-1037, a clinical stage ENaC blocker for pulmonary disea …
  • CG Power and Industrial Solutions Ltd (CGPOWER):企業の財務・戦略的SWOT分析
    CG Power and Industrial Solutions Ltd (CGPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Orphazyme AS (ORPHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Orphazyme A/S (Orphazyme) formerly Orphazyme ApS, is a biopharmaceutical company that develops heat shock protein based therapies for the treatment of orphan protein-misfolding diseases. Its lead product drug candidate arimoclomol is under clinical development for treating neuromuscular dise …
  • Proactis Holdings Plc (PHD):企業の財務・戦略的SWOT分析
    Summary Proactis Holdings PLC (Proactis) is a technology company. The company develops and provides spend control and eprocurement solutions. It offers various solutions such as purchase-to-pay, eCommerce, source-to-contract, and global framework. It provides source-to-contract solutions for supplie …
  • Fluor Corp (FLR):電力:M&Aディール及び事業提携情報
    Summary Fluor Corp (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other services t …
  • Innophos Holdings Inc (IPHS):企業の財務・戦略的SWOT分析
    Innophos Holdings Inc (IPHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. ValiRx uses GeneICE technology, which enables silen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆